The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

a study on Lupus

Summary

Eligibility
for people ages 18-76 (full criteria)
Location
at Torrance, California and other locations
Dates
study started
completion around
Principal Investigator
by George Karpouzas

Description

Summary

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).

Official Title

A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE)

Keywords

Systemic Lupus Erythematosus, Toll-like Receptor 7, Toll-like Receptor 8, WILLOW, Adults, SLE, CLE, Lupus, Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, M5049, Enpatoran, LTE, M5049 low dose, M5049 medium dose, M5049 high dose, M5049 very high dose

Eligibility

You can join if…

Open to people ages 18-76

  • Are active SCLE, DLE and/or SLE that have completed the 24 week Treatment of the Willow Study
  • Have a Body Mass Index (BMI) within the >= 40 kilograms per meter square (inclusive) at Screening
  • Other protocol defined inclusion criteria could apply

You CAN'T join if...

  • Participants who experienced serious event(s) related to the study intervention during the WILLOW study
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Long Term Extension (LTE) study participation
  • Ongoing or active clinically significant viral (including Severe acute respiratory syndrome coronavirus 2 [(SARS-CoV-2)], bacterial or fungal infection, or any major episode of infection requiring hospitalization
  • Received LTE prohibited medication during the WILLOW study or after the WILLOW study Week 24
  • Participation in any other investigational drug study after the WILLOW study Week 24
  • Other protocol defined exclusion criteria could apply

Locations

  • The Lundquist Institute at Harbor-UCLA Medical Center accepting new patients
    Torrance California 90502 United States
  • Centro Medico del Angel accepting new patients
    Mexicali Mexico

Lead Scientist at UCLA

  • George Karpouzas
    HS Clinical Professor, Medicine. Authored (or co-authored) 58 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Links
Trial Awareness and Transparency website
ID
NCT05540327
Phase
Phase 2 Lupus Research Study
Study Type
Interventional
Participants
Expecting 532 study participants
Last Updated